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TREX1 is an endoplasmic reticulum (ER)-associated
negative regulator of innate immunity. TREX1 muta-
tions are associated with autoimmune and autoin-
flammatory diseases. Biallelic mutations abrogating
DNase activity cause autoimmunity by allowing
immunogenic self-DNA to accumulate, but it is
unknown how dominant frameshift (fs) mutations
that encode DNase-active but mislocalized proteins
cause disease. We found that the TREX1 C terminus
suppressed immune activation by interacting with
the ER oligosaccharyltransferase (OST) complex
and stabilizing its catalytic integrity. C-terminal trun-
cation of TREX1 by fs mutations dysregulated the
OST complex, leading to free glycan release from
dolichol carriers, as well as immune activation
and autoantibody production. A connection between
OST dysregulation and immune disorders was de-
monstrated in Trex1/ mice, TREX1-V235fs patient
lymphoblasts, and TREX1-V235fs knock-in mice. In-
hibiting OST with aclacinomycin corrects the glycan
and immune defects associated with Trex1 defi-
ciency or fs mutation. This function of the TREX1 C
terminus suggests a potential therapeutic option for
TREX1-fs mutant-associated diseases.
INTRODUCTION
Mammalian cells have evolved negative regulators of innate im-
munity to protect against autoimmune activation. These negativeImregulators either remove immunogenic self-ligands accumulated
in the wrong place (e.g., self-DNA in the cytosol) (Holm et al.,
2013) or act upstream to prevent production of self-ligands or
their precursors (e.g., erroneous lipids or glycans with abnormal
branching) (Green et al., 2007; Kawasaki et al., 2013). We have
focused on the negative regulator TREX1 (DNase III), a 30/50
exonuclease (Hasan et al., 2013; Yan et al., 2010). As a single
locus, TREX1 mutations are associated with a surprisingly
broad spectrum of autoimmune and inflammatory phenotypes,
including Aicardi-Goutie`res syndrome (AGS), familial chilblain
lupus (FCL), systemic lupus erythematosus (SLE), and retinal
vasculopathy with cerebral leukodystrophy (RVCL) (Crow and
Rehwinkel, 2009). TREX1 protein has an exonuclease domain
at the N terminus and an ER localization domain at the C termi-
nus, containing a single-pass transmembrane (TM) motif tail-
anchoring TREX1 on the ER (Lee-Kirsch et al., 2007; Lindahl
et al., 2009). Recessive missense mutations in the TREX1 DNase
domain (e.g., D18N and D200N [Fye et al., 2011; Lehtinen et al.,
2008]) are predominantly associated with AGS, an early-onset
autoimmune disease with severe clinical presentation. In con-
trast, dominant frameshift mutations that truncate the C terminus
remain DNase active (e.g., V235fs and P272fs [de Silva et al.,
2007; Lee-Kirsch et al., 2007; Richards et al., 2007]) and largely
associate with RVCL (and in some cases SLE) with later
onset and less severe disease (see summary diagram in Fig-
ure S1A; Crow and Rehwinkel, 2009; Richards et al., 2007).
In AGS the diminished TREX1 DNase activity leads to accumula-
tion of self-DNA from replication debris (Yang et al., 2007) or
endogenous retroelements (Stetson et al., 2008), probably con-
tributing to sterile inflammation. However, such etiology does
not explain disease caused by C-terminal frameshift mutations.
Here, we report an unexpected new function of the TREX1 C ter-
minus for maintaining catalytic fastidiousness of the ER enzyme
complex oligosaccharyltransferase (OST). OST dysregulationmunity 43, 463–474, September 15, 2015 ª2015 Elsevier Inc. 463
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Figure 1. TREX1 C Terminus Plays a Critical Role in Suppressing Immune Activation
(A) Quantitative RT-PCR analysis of Cxcl10mRNA (an ISG) in lymphoblasts from TREX1 patients and healthy controls. Three healthy controls (pooled in HC) and
six RVCL patients (V235fs) are shown.
(B) Immunoblot analysis of full-length and C-terminal truncated TREX1 in control and patient cells. HMGB1 is used as a loading control.
(legend continued on next page)
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caused by TREX1 C-terminal truncation leads to hydrolytic
release of free glycans from dolichol (lipid)-linked oligosaccha-
rides (LLO), as well as immune activation and autoantibody pro-
duction. The identification of distinct functions of the TREX1
N-terminal and C-terminal regions, with connection between
OST and immune disorders in the latter case, provides a
biochemical framework for understanding the two classes of
TREX1 diseases and more specifically the effects of RVCL
frameshift truncations.
RESULTS
TREX1 C Terminus Plays a Critical Role in Suppressing
Immune Activation
We reported that Trex1 deficiency causes cell-intrinsic activation
of immune genes (e.g., IFN-stimulated genes or ISGs) in an
IFN-independent manner (Hasan et al., 2013), but the roles of
the C-terminal ER localization domain in activation of immune
genes were unclear. Thus, we examined lymphoblasts from six
unrelated RVCL patients carrying the dominant TREX1-V235fs
mutation and three healthy controls with normal TREX1. All
RVCL patient cells had elevated ISG transcripts (e.g., CXCL10
mRNA, Figure 1A). Because TREX1-V235fs is dominant, we
confirmed the dual expressions of normal and C-terminal trun-
cated TREX1 in RVCL patient cells with a new antibody against
the TREX1 N terminus (Figure 1B). The truncated TREX1 protein
is DNase active but mislocalized throughout the cell (Richards
et al., 2007). We also found that human lymphoblasts are devoid
of components of cytosolic DNA sensing pathway such as cGAS
and STING and that lymphoblasts activate IFN expression in
response to RNA, but not DNA, stimulation (Figures S1B and
S1C). These data suggested that the TREX1C terminus (perhaps
involving ER localization) had a key role in suppressing cell-
intrinsic immune gene activation, independent of DNA sensing.
To examine the function of TREX1’s C terminus, we reconsti-
tuted mouse Trex1/ fibroblasts (MEFs) with normal human
TREX1 (KO-TREX1) that localizes to the ER, a C-terminal trun-
cation (KO-TREX1DTM) that localizes throughout the cell, a
chimera that mislocalizes the truncated TREX1 to the nucleus
(KO-TREX1DTM-nls), TREX1’s C terminus fused to GFP that
localizes to the ER (GFP-TM), or GFP alone (KO-GFP) (Figures
1C and 1D). Normal TREX1 strongly suppressed Ifit1 mRNA
expression and overall ISG signature induction in Trex1/ cells.
In contrast, TREX1DTM only partially suppressed ISG expres-
sion (Figures 1E–1G), and the residual rescuing activity was likely
contributed from the active DNase domain mislocalized in the(C) Diagrams of human TREX1 rescue constructs used in (D)–(H).
(D) Fluorescent microscopy of the TREX1 constructs. Trex1/ MEFs reconstitu
FLAG antibody (green) or unstained (GFP-TM) and an ER marker anti-Calnexin (
(E) Quantitative RT-PCR analysis of Ifit1mRNA (an ISG) in the indicated Trex1/ r
Gapdh.
(F andG) Quantitative RT-PCR analysis of indicated gene groups in Trex1/ rescu
caused by Trex1/ as shown previously (Hasan et al., 2013). The IFN group conta
Irf7; the Inflammatory gene group contains Il6, Il17a, Tnf,Ccl3, and Il23a; and the C
one gene. Gene expression values were normalized to the housekeeping gene G
signature analysis. (G) Trex1/ rescue cells. Only the ISG group genes are show
KO-GFP ISG dataset is presented in (F) and (G).
*p < 0.05, **p < 0.01, ***p < 0.001, ns indicates not significant (same throughout).
indicate SEM (same throughout). Unpaired t test (A, E); Mann-Whitney test (F, G
Imcytoplasm. Consistent with this, TREX1DTM-nls, which localizes
to the nucleus, has only marginal activity in suppressing ISG
expression (Figures 1E–1G). We confirmed that TREX1DTM is
DNase active on both ssDNA and dsDNA substrates in vitro
and in cells (Figures S1D–S1G). Conversely, GFP-TM that
localized to the ER reduced ISGs by 3- to 5-fold (Figures 1E–
1G), suggesting that TREX1 C terminus is functional by itself
(without the DNase domain) for suppressing ISG induction, and
that both N-terminal DNase domain and C-terminal ER localiza-
tion domain are required for fully suppressing ISG activation in
Trex1/ MEFs. Collectively, our data with RVCL patient cells
and Trex1/ rescue MEFs suggest that the TREX1 C terminus
is critical for suppressing cell-intrinsic immune activation, with
a yet-to-be-identified role in ER biology that might be the under-
lying cause of RVCL.
OST Activity Is Dysregulated in Trex1–/– Cells
A major function of the ER is asparagine-linked (N-linked) glyco-
sylation of nascent polypeptides. This involves biosynthesis of
the 14-sugar glycan glucose3mannose9N-acetylglucosamine2
(G3M9Gn2) linked to the polyisoprene lipid dolichol by a labile
pyrophosphate bond, i.e., a lipid-linked oligosaccharide (LLO).
The ER enzyme OST transfers the G3M9Gn2 glycan to aspara-
ginyl residues in the context Asn-X-Ser/Thr of nascent proteins.
However, under conditions such as ER stress (Gao et al., 2011),
viral infection (Gao et al., 2011), or hereditary metabolic error
(Cline et al., 2012), LLO hydrolysis can be stimulated and free
glycans liberated from LLOs begin to accumulate in the ER
lumen (Figure S2A). The free glycans are processed to smaller
fragments that potentially span the entire luminal space from
ER to Golgi, endosomes, and lysosomes (Gao et al., 2011). Aber-
rant mammalian glycans can be immunogenic and cause auto-
immune phenotypes as in a-mannosidase II deficiency (Chui
et al., 2001; Green et al., 2007).
To explore potential links between TREX1 and ER glycan
metabolism, we used fluorophore-assisted carbohydrate elec-
trophoresis (FACE) (Gao and Lehrman, 2006), a quantitative
technique for assessment of steady-state concentrations of
a variety of cellular saccharides. Surprisingly, Trex1/ MEFs
contain 6-fold more total free glycans in vesicular compartments
(defined by cell association after selective plasma membrane
permeabilization with streptolysin-O [SLO]) compared to wild-
type cells (Figure 2A), with a 40% reduction of G3M9Gn2-LLO
(the precursors of free glycans) (Figure S2B). Steady-state LLO
measurements are not expected to decrease to the same extent
as the increase observed for free glycans, because LLOs areted with the indicated rescuing construct were fixed and stained with an anti-
red).
escueMEFs. Gene expression value was normalized to the housekeeping gene
eMEFs. (F) KO-GFP cells compared toWT cells demonstrate the ISG signature
ins Ifnb1, Ifna4, and Ifng; the ISG group containsCxcl10, Ifit1,Oasl2, Isg15, and
ontrol gene group containsHprt,Gapdh, and Actb. Each data point represents
apdh. Fold increase was then determined by normalizing to WT to aid group
n. No difference was found in other gene groups. To aid comparison, the same
Data are representative of at least three independent experiments. Error bars
). See also Figure S1.
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Figure 2. TREX1 C Terminus Regulates Hydrolysis of Lipid-Linked
Oligosaccharides
(A) FACE analysis of vesicular free glycans from SLO-permeabilized WT and
Trex1/MEFs. Similar results were seen with whole cells. L indicates glucose
oligomer glycan ladder (same throughout). Quantification shown in the bar
graph on the right. WT normalized to 1.
(B) Quantification of total free glycans from WT and Trex1/ mouse BMDMs,
kidneys, and serum. FACE gels are shown in Figure S2. Each data point is the
average value from one individual mouse.
(C) FACE analysis of total free glycans from WT and Trex1/ MEFs recon-
stituted with the indicated rescuing construct. Data are representative of at
least three independent experiments.
Unpaired t test (A, B).continuously resynthesized while free glycans accumulate. With
an ‘‘in-cell’’ assay, we showed directly that free glycan formation
by LLO hydrolysis was accelerated in Trex1/MEFs, indicating
OST dysfunction (Figure S2C). However, in Trex1/ cells we did466 Immunity 43, 463–474, September 15, 2015 ª2015 Elsevier Inc.not observe gross qualitative or quantitative changes in total
cellular N- or O-linked glycans (Figures S2D and S2E). Free
glycan accumulation in Trex1/ cells appeared independent
of ER stress, because Trex1/ cells lacked a strong ER stress
response, although Trex1/ cells might be more sensitive to
exogenous ER stressors (Figures S2F–S2J).
Like MEFs, Trex1/ bone-marrow-derived macrophages
(BMDMs), heart, and kidney all contained more free glycans
compared to WT (Figures 2B, S2K, and S2L). We also detected
more free glycans inTrex1/mouse serumcompared toWT (Fig-
ures 2B and S2L), consistent with secretion. Because they bind to
Con A efficiently, Trex1/ MEF-free glycans are probably high-
mannose, hybrid, or biantennary-complex type (Figure S2N).
Because ER localization of TREX1 is required for suppressing
the ISG signature (Figure 1), we examined its role in controlling
free glycan production by FACE analysis of rescued Trex1/
MEFs (Figure 2C). Whereas WT TREX1 strongly suppressed
free glycan accumulation in Trex1/ cells, mislocalized but
DNase-active TREX1DTM and TREX1DTM-nls failed to appre-
ciably reduce free glycans levels. Equally important, DNase-
inactive TREX1-D18N that was properly ER localized diminished
free glycan concentrations to those of WT and TREX1 rescue
cells, showing that DNase activity is dispensable for TREX1 to
suppress free glycan accumulation. Thus, the TREX1 C terminus
has an unexpected DNase-independent function associated
with ER glycan metabolism.
Products of OST Dysregulation Are Immunogenic
We next asked whether Trex1/ free glycans might contribute
to immune activation. Free glycan pools from WT and Trex1/
cells were incubated with wild-type BMDMs, and then expres-
sion of immune and housekeeping genes was measured by a
qPCR array. Free glycan pools from Trex1/ cells, but not
fromWT cells, induced strong expression (5- to 20-fold increase)
of many ISGs in wild-type BMDMs (Figure 3A), but not house-
keeping, IFN, and inflammatory genes, similar to the ISG sig-
natures of Trex1/ and RVCL patient cells (Figure 1). We also
treated the free glycan pool with a combination of DNase,
RNase, and proteases or eluted them from FACE gels to elimi-
nate contamination concerns. The treated and gel-purified
glycan pool was still able to induce ISGs in wild-type BMDMs
(Figures 3A and 3B). In contrast, Man5-9GlcNAc2 high-mannose
N-glycan mixtures from RNase B after PNGase treatment (con-
sisting of at least five discrete species by FACE) did not stimulate
ISGs when added to macrophages (Figure 3C). This suggests
that bioactive Trex1/ free glycans are not typical high-
mannose containing structures; perhaps they are glucosylated
or paucimannose-type instead. Indeed, we found that Trex1/
free glycan pools contain smaller differing structures compared
to RNaseB N-glycan (Figure 3C). Using BMDMs derived from
specific knockout mice, we also determined that free glycan-
induced immune activation is TBK1 dependent, but cGAS-
STING independent (Figures S3A–S3D). We note that in these
experiments free glycans were added exogenously, which might
lead to activation of immune pathways that are different from
pathways that might be activated when glycan pools are derived
endogenously in Trex1/ cells. Nevertheless, these data sug-
gest that free glycans have the potential to induce the ISG signa-
ture commonly associated with TREX1 diseases.
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Figure 3. Immunological and Biochemical
Consequences of OST Dysregulation
(A) Quantitative RT-PCR array analysis of immune
gene activation in wild-type BMDMs treated with
indicated glycans. Free glycans from WT and
Trex1/ MEFs were untreated or treated with a
cocktail of DNase, RNase and protease before
being added to BMDMs for 20 hr. Each data point
represents one gene as in Figure 1F.
(B and C) Quantitative RT-PCR analysis of immune
gene activation in wild-type BMDMs treated with
indicated glycans. Glycan source in (B) is free
glycans isolated from Trex1/ MEFs (pooled
glycans) or from FACE gels (gel-purified glycans).
Glycan source in (C) is N-glycan isolated from
increasing amount of RNase B protein (Sigma
Cat#R1153, PNGase digest) or from buffer alone.
Ifit1 and Cxcl10 mRNA were analyzed by qRT-
PCR. Right, FACE analysis of glycans used in (B)
and (C).
(D) In-cell N-glycosylation assay. WT and Trex1/
MEFs were permeabilized with SLO and incubated
with reaction buffer (see Experimental Procedures)
and control or acceptor peptide. Only the acceptor
peptide contains one N-glycosylation site. Trans-
ferred N-glycans were then cleaved by EndoH and
analyzed by FACE (top gel). Free glycans were also
analyzed from the same experiment (bottom gel).
Free glycans quantified in this assay are from LLO
hydrolysis during the assay, not the pre-existing
free glycans in the cell (much smaller in size). Data
are representative of at least two independent
experiments.
Error bars indicate SEM (same throughout). Mann-
Whitney test (A); unpaired t test (B). See also
Figure S3.TREX1 Helps OST Act as a Peptide-Dependent
Transferase Rather than a Hydrolase
Converting LLOs to free glycans should lead to less donor sub-
strate available for N-glycosylation and loss of glycan shielding
of potentially antigenic sequences. To test this possibility, weImmunity 43, 463–474, Seperformed the in-cell OST activity assay
(a diagram in Figure S3E). WT and
Trex1/ MEFs were permeabilized by
SLO and incubated with reaction buffer
containing nucleotide sugars for LLO
synthesis and control or acceptor pep-
tide. Only the acceptor peptide contains
a N-glycosylation site. Both transferred
N-glycans (cleaved with EndoH) and
free glyans (from LLO hydrolysis) were
analyzed by FACE. In WT cells, trans-
ferred N-glycans increased and free gly-
cans decreased with acceptor peptide
present, consistent with the fact that
both transfer and hydrolysis activities of
OST utilize the same pool of incoming
substrate (LLOs in the ER membrane,
as shown in Figure S3E). We then
compared each OST activity in WT
versus Trex1/ cells. Although OST hy-
drolysis activity was elevated by 2-fold, acceptor peptide ap-
peared underglycosylated in Trex1/ compared to WT cells
by 2-fold (Figure 3D). This suggests that OST transfer activity
for N-glycosylation might be limiting in permeabilized Trex1/
cells, either due to insufficient LLO, or a kinetic difference inptember 15, 2015 ª2015 Elsevier Inc. 467
the absence of TREX1. Thus, OST is enzymatically active in
Trex1/ cells, but its preference for peptide targets versus wa-
ter might be compromised. We next tried to detect glycosylation
defects in endogenous proteins. However, glycosylation anal-
ysis with live cells (immunoblot analysis of several endogenous
glycoproteins or measurement of total N-linked glycans) failed
to reveal a significant glycosylation defect in Trex1/ cells or
RVCL patients lymphoblasts compared to WT or healthy control
cells, respectively (data not shown). Collectively, these data
suggest that Trex1 deficiency has the potential to cause N-
glycosylation defects, probably affecting proteins with less
favorable acceptor sequons such that a small subset of glyco-
proteins would be primarily affected.
TREX1 Interacts with the OST Complex on the ER
through the C Terminus
Because the absence of TREX1 accelerated LLO hydrolysis
by OST, we asked whether the two enzymes interacted physi-
cally. The mammalian OST complex contains 7–8 subunits,
with two alternative catalytic subunits (STT3A and STT3B)
(Kelleher and Gilmore, 2006). We co-expressed TREX1-V5 and
variousMyc-taggedOST subunits in 293T cells and assessed in-
teractions by immunoprecipitation (IP). We found strong interac-
tions between TREX1 and two subunits, DDOST and RPN1, but
failed to detect interaction with two other subunits, RPN2 and
STT3A (Figure 4A). Immunoprecipitation of OST subunits was
completely dependent upon the presence of TREX1 (Figure 4B).
We validated TREX1:RPN1 and TREX1:DDOST interactions
by reverse IPs (Figure 4C). Notably, C-terminal truncation of
TREX1 (TREX1DTM) drastically reduced the interaction with
RPN1, consistent with OST interacting with TREX1 through its
C terminus (Figure 4D). Immunofluorescence microscopy re-
vealed extensive colocalization of TREX1 and RPN1 at the ER
(Figure 4E).
These data led us to hypothesize that OST might signal the
absence or dissociation of TREX1 from the ER and be involved
in ISG induction in Trex1/ cells. Upon depletion of individual
OST subunits in Trex1/ cells with specific shRNAs, we found
that Rpn1 and Stt3a depletion both suppressed Ifit1 mRNA
expression whereas Rpn2 and Stt3b depletion did not (Figures
4F and S4). These results implicate OST itself in suppressing
cell-intrinsic immune activation caused by disruption of Trex1.
In conjunction with our co-IP studies, we infer that whereas
RPN1 interacts physically with TREX1, STT3A (one of the two
catalytic subunits of OST) appears to control ISGs without an
interaction with TREX1 detectable by co-IP.
Inhibiting OST Activity by Aclacinomycin Corrects
Glycan and Immune Defects in TREX1 Mutant Cells
To better link OST activity with immune disorders, and to explore
this interaction as a therapeutic target, we tested a small phar-
macologically active molecule, aclacinomycin A (Acm) (Bennett
et al., 2013). Acm is FDA approved for treating acute myeloid
leukemia (Majima andOhta, 1987) andwas previously implicated
in impairing OST function. However, the precise mechanism
was unclear (Bennett et al., 2013; Morin and Sartorelli, 1984).
Here, we performed the in-cell OST activity assay (Figure 3D)
in permeabilized WT or Trex1/ MEFs treated with DMSO or
Acm. We found that Acm inhibited both known activities of468 Immunity 43, 463–474, September 15, 2015 ª2015 Elsevier Inc.OST: transfer of glycan to asparaginyl acceptors and LLO hydro-
lysis yielding free glycans (Figures 5A and S5A–S5E). With live
Trex1/ cells, we then found that both LLO hydrolysis and
ISG activation were diminished in parallel after 24 hr of Acm
treatment (Figures 5B and 5C). Acm treatment also reduced
the lysosomal gene signature in Trex1/ cells (Figure S5F),
consistent with a glycosylation defect acting upstream of the
lysosome expansion phenotype that we observed previously
(Hasan et al., 2013). To test Acm in vivo, we treated Trex1+/
and Trex1/ mice with DMSO or Acm for 8 weeks. Trex1/
mice usually show splenomegaly and discoloration of the liver
due to systemic inflammation and autoimmunity, as well as
elevated ISGs especially in the heart (Gall et al., 2012; Hasan
et al., 2013). Acm treatment in vivo significantly reduced the
ISG signature in Trex1/mouse heart and spleen and improved
both spleen and liver phenotypes (Figures 5D and 5E). Impor-
tantly, Acm significantly improved survival of Trex1/mice (Fig-
ure 5F). Collectively, our data suggest that OST dysregulation
is an important contributing factor for TREX1 disease and that
inhibiting OST with Acm might be an efficacious therapeutic
option.
To further validate the therapeutic potential of Acm to treat
TREX1 frameshift patients, we examined OST dysfunction in
lymphoblasts from TREX1 V235fs (RVCL) patients and healthy
controls. All RVCL patient cells had elevated amounts of free
glycan (Figures 6A and 6B) compared to healthy controls. Impor-
tantly, all RVCL patient cells responded to Acm treatment, which
restored free glycan and CXCL10 mRNA levels to normal (Fig-
ures 6C and 6D).
TREX1-V235fs Knock-in Mice Display Elevated Immune
Gene Signature, Free Glycans, and Autoantibodies
To better model human RVCL disease, we generated TREX1-
V235fs knock-in mice (RVCL mouse) (Figure S6A). We con-
firmed the expression of a human TREX1-V235fs truncation
and loss of mouse Trex1 expression in BMDMs of the RVCL
mouse (Figure 7A). Both heterozygous and homozygous
TREX1-V235fs mice are grossly normal and without inflamma-
tion detected in any tissue (data not shown). This suggests
that RVCL mice do not suffer from self-DNA-mediated systemic
inflammation, consistent with clinical findings of RVCL patients
and with mislocalized V235fs DNase being functional. Yet,
RVCL mouse BMDMs express elevated ISGs compared to
WT littermates (Figure 7B), with a 3-fold increase in free glycans
(Figure 7C). We detected strong autoantibody production in
RVCL mouse serum against a spectrum of disease-associated
protein antigens (Figures 7D and 7E). Taken together, TREX1
frameshift mutation cause OST dysregulation and immune dis-
orders, but not DNA-associated systemic inflammation in vivo.
Whether RVCL mice develop vision and neurological symptoms
as in human patients awaits further investigation. Trex1/ mice
have been very useful in studying human TREX1 diseases,
although they do not distinguish different diseases associated
with TREX1 mutations affecting the DNase domain or the C ter-
minus. The RVCL knock-in mouse presented here is thus a
better model for studying diseases associated with TREX1
C-terminal frameshift mutations and will allow testing of
different hypotheses for OST dysregulation leading to immune
disorders.
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Figure 4. TREX1 Interacts with the OST Complex through the C Terminus
(A and B) Immunoblot analyses of TREX1 interaction with subunits of the OST complex. 293T cells were co-transfected with TREX1-V5 and one subunit of the
OST complex as indicated (all Myc-tagged). Immunoprecipitation (IP) was performed with anti-V5 antibody, and precipitated immune complexes were analyzed
by immunoblot with anti-V5 antibody (to detect primary IP of TREX1) and anti-Myc (to detect co-IP of individual OST subunits). The absolute requirement for
TREX1 is emphasized in (B).
(C) Immunoblot analysis of TREX1 interactions with RPN1 and DDOST. 293T cells were transfected with plasmids indicated on top. Immunoprecipitation (IP) was
performed with anti-Myc antibody.
(D) The TREX1 C terminus is required for interaction with RPN1. 293T cells were co-transfected with Myc-RPN1 and the indicated TREX1 (Flag-tagged) plasmids
on top. Co-IP was performed with anti-Flag antibody.
(E) Immunofluorescentmicroscopy analyses of TREX1 and RPN1 colocalization. GFP-TREX1, GFP-TREX1DTM, or GFP-TMwere co-transfected withMyc-RPN1
and immunostained with anti-Myc (red) 24 hr later.
(F) Rpn1 and Stt3a are required for immune activation in Trex1/ cells. Trex1/ MEFs were transduced with lentiviruses expressing specific shRNAs as
indicated. Expression of Ifit1 mRNA was measured by RT-qPCR. Specific knockdown of individual genes was verified by RT-qPCR in Figure S4.
Data are representative of at least three independent experiments. Unpaired t test (F).DISCUSSION
The discordance between the genetics and clinical etiologies of
AGS versus RVCL predicted a novel function of TREX1 associ-
ated with the C terminus and independent of DNase activity.
By focusing on RVCL mutations, we found that truncation of
the TREX1 C terminus dysregulates OST, which like TREX1 is
also ER localized. This finding suggests that mutations disrupt-
ing different parts of TREX1 can cause clinically distinct pheno-
types. We propose that TREX1 AGS (recessive) is caused byImself-DNA sensing when both copies of the DNase domain are
defective, consistent with a requirement for a catalytic function
and severe clinical diseases in childhood. In contrast, TREX1
RVCL (dominant) is probably caused by OST dysregulation
when one copy of TREX1 loses the C terminus, disrupting its
interaction with the OST complex and leading to a plethora of
downstream effects. This is consistent with a slower progression
of RVCL disease, with typical onset in adulthood to older age
(Richards et al., 2007) Moreover, we found that RVCL patient
cells had strong induction of ISGs including CXCL10 mRNA.munity 43, 463–474, September 15, 2015 ª2015 Elsevier Inc. 469
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Figure 5. InhibitingOSTActivity by Aclacino-
mycin Suppresses Free Glycan Release, Im-
mune Activation, and Disease in Trex1–/–
Mice
(A) Acm inhibits both OST activities in Trex1/
cells. Representative images of FACE gels are
shown in Figure S5.
(B and C) FACE analysis of free glycans (B) and
quantitative RT-PCR analysis of immune gene
activation (C) or in WT and Trex1/ MEFs treated
with Acm.WT and Trex1/MEFswere treatedwith
increasing concentration of Acmor DMSO for 24 hr.
Ifit1 mRNA were measured by qPCR. Cells treated
with 2 mM Acm were used for free glycan analysis
in (C).
(D–F) In vivo treatment with Acm. Trex1+/ and
Trex1/ mice were treated with DMSO or Acm
(5 mg/kg) for 8 weeks. Quantitative RT-PCR anal-
ysis of Ifit1 mRNA in mouse heart and spleen after
1 week of treatment are shown in (D) (n = 4).
Representative images of spleen and liver are
shown in (E). Survival curve after 8-week of treat-
ment is shown in (F) (n = 7).
Unpaired t test (A, C, D); logrank test (F).Because CXCL10 inhibits angiogenesis (Taylor et al., 2008) and
induces dissociation of newly formed blood vessels (Bodnar
et al., 2009), elevated CXCL10 could be a major contributor to
systemic vasculopathy in RVCL patients.
How might OST dysregulation lead to such immune pheno-
types in RVCL? For C-terminal truncations of TREX1 typical of
RVCL alleles, we identified two robust biochemical effects on
glycan metabolism. First, dysregulated OST hydrolyzes LLOs
at an abnormal rate. This reduces the steady-state concentra-
tions of LLOs needed for N-linked glycosylation. Within our limits
of sensitivity, we detected no global defects in total N-linked
glycosylation in Trex1/ cells. However, underglycosylation of
a small subset of glycoproteins with unfavorable glycosylation
acceptor sequences (sequons) remains possible. Over an ex-
tended period, the absence of ‘‘glycan shielding’’ could lead to
immune responses to bare epitopes that would induce produc-
tion of novel autoantibodies. Second, accelerated LLO hydroly-470 Immunity 43, 463–474, September 15, 2015 ª2015 Elsevier Inc.sis increased release of free glycans.
These ‘‘self’’ glycans could, for example,
mimic surface glycans of certain patho-
gens that can be recognized by lectin re-
ceptors on macrophages and dendritic
cells to activate immune responses. And
we found that free glycan pools isolated
from Trex1/ cells do have immunogenic
potential, although the exact immune
pathway and glycan structure(s) being
recognized require further investigation.
The ability of OST subunit knockdown
and inhibitor Acm to block both free
glycan release and ISG induction also
supports the immunogenic ‘‘self’’ glycan
hypothesis. Third, the same free glycans
in the ER lumen could compete with
nascent immunomodulatory surface pro-teins for binding to chaperone-lectins and enzyme-lectins in
the secretory pathway to impair their folding or quality control,
or compete with downstream glycan-modifying processes and
ultimately interfere with formation of galectin-stabilized cell sur-
face lattices that might enhance signaling. As a general prece-
dent for these ideas, defects in the glycan-modifying enzyme
a-mannosidase II abnormally increased hybrid N-glycans that
are potential ligands for mannose-binding lectin receptors and
caused SLE-like phenotypes in mice (Chui et al., 2001; Green
et al., 2007). These various hypotheses for OST dysfunction
leading to immune disorders should not be mutually exclusive,
and although testing these ideas experimentally is beyond the
scope of the present study, our new TREX1-V235fs knock-in
mouse model will be very useful for further elucidating the exact
nature of glycan or glycosylation defects caused by TREX1
frameshift mutations, and how they induce immune activation
and autoantibody production.
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B Figure 6. TREX1 RVCL Patient Lympho-
blasts Show Elevated Free Glycans and Im-
mune Gene Expression
(A and B) FACE analysis of free glycans in lym-
phoblasts from RVCL patients and healthy con-
trols. Three healthy controls and three RVCL
patients (V235fs) are shown individually in (A).
Duplicate measurements of total free glycans in
each individual are shown in (B).
(C and D) Free glycan and ISG analysis of lym-
phoblasts from RVCL patients and healthy con-
trols treated with 1 mM Acm for 24 hr.
Data are representative of at least three indepen-
dent experiments. Unpaired t test (B, D).A recently published TREX1-D18N knock-in mouse showed
DNA-mediated systemic inflammation and lupus-like syndrome
similar to Trex1/ mice, although with much longer survival
(>40 weeks) comparing to Trex1/ mice (8–10 weeks) (Grieves
et al., 2015). These observations suggest that both DNA- and
glycan-mediated immune defects contribute to severe disease
in Trex1/ mice. These two new knock-in mouse models (D18N
andV235fs) focusingondistinct functions of TREX1will be incred-
ibly useful tools for further understanding TREX1 biology.
Despite extensive understanding of the composition of the
OST complex and its enzymatic activity and numerous examples
of glycan-lectin interactions in the immune system, OST itself
has never been directly connected to an immune disorder, and
the immune consequences of OST dysregulation have therefore
been unexplored. Thus, our findings will be very useful in
revealing OST’s role in immunoglycobiology, including inhibition
of OST with Acm or similar compounds for treating TREX1C-ter-
minal frameshift diseases.EXPERIMENTAL PROCEDURES
Cells, Viruses, and Mice
Trex1+/–micewereprovidedbyD.Stetson (U.Washington) under an agreement
with D. Barnes and T. Lindahl (Cancer Research UK) (Morita et al., 2004). WT,
P212fs, and D18N human skin fibroblasts were kindly provided by M.-A. Lee-Immunity 43, 463–474, SeKirsch (TUDreston,Germany).HeLa and293Tcells
have been described (Yan et al., 2010). These cells
were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% (v/v) heat-inactivated
fetal calf serum (FCS), 2 mM L-glutamine, 10 mM
HEPES, and 1 mM sodium pyruvate (complete
DMEM) with the addition of 100 U/ml penicillin
and 100 mg/ml streptomycin and cultured at 37C
with 5% CO2. EBV-transformed lymphoblasts
from healthy controls and TREX1 RVCL patients
were maintained in RPMI with the same 10% FCS
and supplements. Bone-marrow-derived macro-
phages were generated as described (Hasan
et al., 2013). VSV-GFP (Das et al., 2006) were pro-
vided by A.K. Pattnaik (U. Nebraska). Cells were in-
fectedwith the indicatedvirus,MOI, and timepoints
andwashed three timeswith13PBSbefore subse-
quent analysis. For Trex1/ MEFs reconstituted
with various TREX1 rescuing constructs, WT or
mutant or truncated TREX1 was cloned into retro-
viral MRX-ibsr vector (Saitoh et al., 2009) (a kind
gift fromS. Akira) usingEcoRI andNotI sites. Retro-viruseswerepackaged in 293Tcells andused for infectionofTrex1/MEFs fol-
lowed by selection with blasticidine (Sigma). For shRNA knockdowns, Trex1/
MEFswere transducedwith lentiviruses expressing specific shRNA (pLKOsys-
tem, Addgene) and selected with puromycin. DNA oligos used for constructing
shRNA plasmids are shown in Table S1. In vivo experiments with Acm were
done by i.p. injections three times per week for 10 weeks. Stocks of DMSO
and Acm were further diluted in PBS to obtain 100 ml total volume per injection
for each mouse. Some mouse tissues were harvested on day 7 after treatment
for RNA and disease phenotype analysis. Experiments carried out in BSL2 con-
ditions were approved by the Environmental Health & Safety Committee at UT
Southwestern Medical Center. Experiments involving human andmousemate-
rialswere approved by the ICUACand IRBof UTSouthwesternMedical Center,
the Washington University School of Medicine, and NIAID (LIP16).
Generation of Mice Expressing V235fs Mutant Human TREX1
These mice were generated by Ozgene using a C57BL/6 targeting strategy as
part of a contract with NIAID, NIH. Conditional humanization of the mouse
Trex1 coding exon was performed by floxing exon 2 and knocking in a human
cDNA bearing the V235fs mutation followed by a PGK-Neo cassette. The hu-
man cDNAwas fused to the UTR sequence from exon 2 and its splice acceptor
site and positioned downstream of the Neo cassette in the targeted locus. The
PGK-Neo cassette was flanked by FRT sites and was deleted using FLPe re-
combinase. The gene product containing the human cDNA was expressed af-
ter Cre-mediated deletion of mouse exon 2. Mice genotyping was performed
with the following primers: CKI_LoxP primers, CKI_LoxP_3b (50-CAGCTCAGC
CCTTCCCTTCAGCAG-30) and CKI_LoxP_5b (50-ACCCTGCCCTCCAGCTTC
TAGTGG-30). The use of mice in this study followed a protocol (LIG-16E)
approved by the National Institute of Allergy and Infectious Diseases Animal
Care and Use Committee.ptember 15, 2015 ª2015 Elsevier Inc. 471
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Figure 7. TREX1-V235fs Knock-in Mouse Display Elevated Free Glycan, ISG Signature, and Autoantibodies
(A) Immunoblot analysis of TREX1 in BMDMs isolated from two independent WT or V235fs-KI homozygous mice. Asterisk (*) indicates a background band.
(B) Quantitative RT-PCR analysis of ISGs in BMDMs of indicated genotype.
(C) FACE analysis of free glycans in BMDMs of indicated genotype.
(D and E) Autoantibody array analysis of serum isolated from WT, V235fs heterozygous, or homozygous (8 months old) mice. Representative autoantibodies are
shown in (E). n = 3. Data are representative of at least two independent experiments.
Unpaired t test (B, C, E). See also Figure S6.Reagents and Antibodies
TRI Reagent (Invitrogen) was used for RNA isolation. Lipofectamine 2000
(Invitrogen) was used for nucleic acid transfections. Aclacinomycin A was
purchased from Santa Cruz (sc-200160). Antibodies used in this study
include anti-TREX1 (raised against the N terminus, generated in-house, rabbit,
1:2,000 dilution), anti-STING (rabbit; 1:1,000 dilution; D2P2F; Cell Signaling),
anti-TBK1 (rabbit; 1:1,000 dilution; D1B4; Cell Signaling), anti-cGas (MB21D1)
(rabbit; 1:200 dilution; HPA031700; Sigma), anti-Tubulin (mouse; 1:2,000 dilu-
tion; B-5-1-2; Sigma), anti-HMGB1 (rabbit; 1:2,000 dilution; ab18256; Abcam),
anti-GRP78 (rabbit; 1:1,000 dilution; ab21685; Abcam), anti-V5 (mouse;
1:5,000dilution;R-960-25; LifeTechnologies), anti-Myc (rabbit; 1:2,000dilution;
sc-40 ac; Santa Cruz), and anti-TREX1 antibody (mouse; 1:200 dilution; sc-
271870; Santa Cruz). Secondary antibodies (1:4,000 dilution; GE Healthcare)
were used for immunoblot analysis according to standard protocols.
qRT-PCR Analysis, qPCR Array, Fluorescence Microscopy, and
FACS
RNA isolation and qRT-PCR analysis were performed as described previously
(Hasan et al., 2013). Oligonucleotides are listed in Table S1. qPCR array ana-472 Immunity 43, 463–474, September 15, 2015 ª2015 Elsevier Inc.lyses of immune gene profiles were performed with custom-ordered PCR array
plates containing primer sets pre-aliquoted (Bio-Rad). Each primer set was
validated by Bio-Rad and in house. For microscopy, cells grown on coverslips
were fixed in 4% (wt/vol) paraformaldehyde and were permeabilized and
stained by standard protocols. Samples mounted in Vectashield mounting
medium containing DAPI (4,6-diamidino-2-phenylindole; Vector Laboratories)
were imaged with a Zeiss Imager M2 fluorescence microscope equipped
with AxioVision software. The following antibodies were used for immunostain-
ing: anti-calreticulin (Abcam, Ab4-100), anti-FLAG (Sigma, F1804), anti-V5 (Invi-
trogen, R960-25), anti-Tubulin (Sigma, B-5-1-2), with Alexa Fluor 488 and 546
tagged secondary antibodies (Invitrogen, A21202, A21206, A10036, and
A10040).
Fluorophore-Assisted Carbohydrate Electrophoresis
FACE analysiswas used to assess total N- andO-linkedglycans, LLOs, and free
glycans. Cultured cells and snap-frozen mouse tissues were disrupted in
methanol, and the resulting suspensions were processed for FACE analyses
as described (Gao and Lehrman, 2006). A three-phase extraction process
yielded an aqueous phase containing neutral free glycans (purified further by
deionization) and an interfacial layer which was extracted with chloroform:me-
thanol:water (10:10:3) to separate soluble LLOs (which were subsequently
depleted of neutral saccharides by ion-exchange chromatography) from insol-
uble N-linked and O-linked glycoproteins. The glycan units of LLOs were
released with weak acid, the N-glycans were released with peptide:N-glycosi-
dase F (C. meningosepticum, Prozyme) or Endoglycosidase H (S. picatus,
New England Biolabs), the O-glycans were released with base and sialic acids
removed with weak acid, and all three glycan fractions were further purified
with ion-exchange resins. All glycans were conjugated with 7-amino-1,3-naph-
thalenedisulfonic acid (ANDS) and resolved on an oligosaccharide profiling gel,
with all loads normalized either to total protein in the chloroform:methanol:water
(10:10:3) insoluble residue or total cell number. Glucose oligomers (with four to
sevenglucosyl residues)andknownLLOglycanswerealso loadedasstandards.
Fluorescently labeledoligosaccharideswere detectedwith either aBioradFluor-
S scanner and quantified with Quantity-One software, or a UVP Chemidoc-ItII
scanner and quantified with VisionWorks software or ImageJ software.
In-Cell OST Activity Assay
SLO cell permeabilization was performed as described in Gao et al. (2011). In
brief, Trex1/ and WT MEFs were grown to 80%–90% confluency on 0.1%
gelatin coated plates to prevent loss of cells thorough the permeabilization
process. Cells were subsequently washed with cold PBS twice and later incu-
bated for 5 min with SLO (2 U/ml) on ice. Cells were then washed twice with
cold PBS and incubated for 5 min in transport buffer (78 mM KCl, 4 mM
MgCl2, and 50 mM K-HEPES [pH 7.2]) at 37
C followed by a 10 min incubation
on ice in the same buffer to allow for the cytosolic content to diffuse out. Cells
were next incubated for 60min in the reaction buffer (400 mMUDP-Glc, 200 mM
UDP-GlcNAc, 50 mM GDP-Man, 2 mM AMP, 10 mg/ml castanospermine, and
40 mg/ml deoxymannojirimycin in transport buffer) with either 50 mM of control
peptide or acceptor peptide and with or without Aclacinomycin A. After the in-
cubation, cells were washed twice with cold PBS and disrupted by addition of
methanol for further FACE analysis.
Co-immunoprecipitation
Approximately 23 106 293Twere transfectedwithwild-type ormutant TREX1-
V5 plasmids and c-Myc OST subnits (STT3A, DDOST, RPN1, or RPN2). Cells
were subsequently collected, washed once with PBS, lysed in IP lysis buffer
(20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.5% NP-40, and 1x protease inhib-
itor mixture), and centrifuged at 20,0003 g for 20min at 4C. The supernatants
were mixed with primary antibody and Dynabeads Protein G (Life Technology)
and incubated overnight at 4C. The following day, the beads were washed
once with IP buffer, then twice with high-salt IP buffer (500 mM NaCl), and
finally once with low-salt IP buffer (50 mM NaCl). Immunocomplexes were
eluted in 33 sample buffer and boiled at 95C for 10 min. Samples were
analyzed by immunoblotting.
Exonuclease Activity Assay
Exonuclease activity assaywas performed as described inGehrke et al. (2013).
In brief, approximately 13 106 293T were transfected with wild-type or mutant
TREX1-V5 plasmids. The post-nuclear supernatant, isolated as described
above,wasmixedwith anti-V5 agarose beads (Bethyl) and incubated overnight
at 4C. The next day the beadswerewashed twicewith IP buffer and twicewith
low-salt IP buffer. Washed beads were resuspended in 50 ml of DNase buffer
(20 mM Tris-HCl [pH 7.4], 5 mM MgCl2, 2 mM DTT, 100 mg/ml BSA, and
0.5% NP-40). Either ssDNA oligo (30-mer) or dsDNA (annealed 30-mer with
30 overhang resembling cleavage by KpnI, oligo sequence in Table S1) were al-
lowed to intercalate SYBRGreen II or SYBRGreen I, respectively (Life Technol-
ogies), for 30 min at 37C in DNase reaction buffer (20 mM Tris-HCl [pH 7.4],
5 mM MgCl2, 2 mM DTT, 100 mg/ml BSA, 1/1,200 SYBR Green, and 10 ng/ml
DNA). A volume of 15 ml of TREX1 bound beads wasmixed with 90 ml of DNase
reaction buffer followed by real-time quantification of DNA/SYBR using a
SynergyHT microplate reader (Biotek) done in triplicates. Beads were later
collected for detection of TREX1 expression by immunoblot analysis.
Statistical Methods
Data are presented as the mean ± SEM. Graphpad Prism 6 was used for sta-
tistical analysis. Statistical tests performed were indicated in figure legend.
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.ImSUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.immuni.2015.07.022.
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